NRx Pharmaceuticals, Inc.
NRXP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 59.9% | – | – | – |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $3 | $3 | $0 |
| SG&A Expenses | $3 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $4 | $4 | $4 |
| Operating Income | -$4 | -$4 | -$4 | -$4 |
| % Margin | -1,662.8% | – | – | – |
| Other Income/Exp. Net | -$2 | -$14 | -$2 | -$5 |
| Pre-Tax Income | -$6 | -$18 | -$6 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$18 | -$6 | -$9 |
| % Margin | -2,433.9% | – | – | – |
| EPS | -0.27 | -0.98 | -0.34 | -0.86 |
| % Growth | 72.4% | -188.2% | 60.5% | – |
| EPS Diluted | -0.27 | -0.98 | -0.34 | -0.86 |
| Weighted Avg Shares Out | 22 | 18 | 16 | 11 |
| Weighted Avg Shares Out Dil | 22 | 18 | 16 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$18 | -$6 | -$9 |
| % Margin | -2,416.1% | – | – | – |